References
- Alkhatib NS, Erstad B, Ramos K, et al. Pricing methods in outcome-based contracting-δ1: cost-effectiveness analysis and cost utility analysis-based pricing. J Med Econ. 2020;23(11):1215–1222.
- Alkhatib NS, Ramos K, Erstad B, et al. Pricing methods in outcome-based contracting-δ2: willingness-to-pay-based pricing. J Med Econ. 2020;23(11):1223–1229.
- Alkhatib NS, Erstad B, Ramos K, et al. Pricing methods in outcome-based contracting-δ3: reference-based pricing. J Med Econ. 2020;23(11):1230–1236.
- Alkhatib NS, Bhattacharjee S, McBride A, et al. Pricing methods in outcome-based contracting-δ4: safety-based pricing. J Med Econ. 2020;23(11):1237–1245.
- Alkhatib NS, McBride A, Bhattacharjee S, et al. Pricing methods in outcome-based contracting-δ5: risk of efficacy failure-based pricing. J Med Econ. 2020;23(11):1246–1255.
- Alkhatib NS, Slack M, Bhattacharjee S, et al. Pricing methods in outcome-based contracting-δ6: adherence-based pricing. J Med Econ. 2020;23(11):1256–1265.
- Griffith D. Four types of price variation. Laramie (WY); March 2013 [accessed December 2019]. Available from: http://www.uwagec.org/rightrisk/presentations/2013_03_26_DGriffithMarketing/1_Introduction/1_FourTypesPriceVariation.pdf
- Bodoh-Creed A, Boehnke J, Hickman B. Using machine learning to predict price dispersion. Scholars at Harvard. [accessed December 2019]. Available from: https://scholar.harvard.edu/files/boehnke/files/bcbh_machine_learning_price_dispersion.pdf
- Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York (NY): Oxford University Press; 2011.
- Soria J, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113–125.
- RedBook Online [subscription database onlie]. Greenwood Village (CO): Truven Health Analytics. [accessed December 2019; updated periodically]. Available from: http://micromedex.com/products/product-suites/clinical-knowledge/redbook
- Kaltenboeck A, Bach P. Value-based pricing for drugs: theme and variations. JAMA. 2018;319:2165–2166.
- PhRMA. Value-based contracts: 2009-Q1 2018. USA; 2018 [accessed December 2019]. Available from: http://phrma-docs.phrma.org/files/dmfile/PhRMA_ValueBasedContracts_V9.pdf
- Seeley E, Kesselheim AS. Outcomes-based pharmaceutical contracts: an answer to high U.S. drug spending. [accessed December 2019]. Available from: https://www.commonwealthfund.org/publications/issue-briefs/2017/sep/outcomes-based-pharmaceutical-contracts-answer-high-us-drug
- American Cancer Society. Chronic Lymphocytic Leukemia (CLL). [accessed December 2019]. Available from: https://www.cancer.org/cancer/chronic-lymphocytic-leukemia.html
- Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17:1616–1622.
- Yu HA1, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–2247.